Abstract 2839
Background
Obesity carries a high risk of breast cancer with worse treatment outcome. Different molecular subtype and prognostic factors are linked to high body mass index (BMI) and affects overall and progression-free survival.
Methods
All 950 breast cancer patients presented to kasr Alainy oncology center (NEMROCK) from 2004 - 2014 at Al kasr alainy oncology center (NEMROCK) were followed up with a median period of 4.2years till Dec 2018. The body mass index (BMI) was assessed at diagnosis in 760 female patients. Disease-free survival (DFS) and overall survival (OS) were assessed and compared between three groups: non-obese (BMI <30), obese (BMI 30-34.9) and severely obese (BMI >40).
Results
The mean age was 50.1 years with Obesity in 63.29% of cases (23.82% and 39.47% in obese and severely obese respectively). Significant correlations between non-obese and severely obese with age (52 vs.48 years, p < 0.001), menopausal status (31.3 vs.46.9%, p < 0.001), molecular types (non- luminal; 25 vs. 50% p < 0.011), Her2 status (44.4 vs. 27.2%, p = 0.014) and hormonal therapy (Tamoxifen alone, 44.3 vs. 30.4%, p = 0.001). Mean Overall survival(OS) was significantly better in non-obese groups compared to obese and severely obese (102.5, 80, 88months, P=value 0.019), with no impact on DFS (p = 0.40).In multivariate analysis, lymph node stage (p < 0.001; OR: 1; 95% CI: 0.07-0.46), BMI (p = 0.001; OR: 1; 95% CI: 0.14-0.61), and hormonal treatment tamoxifen alone(p = 0.001; OR: 1; 95%CI: 1.4-16.4) remained significantly associated with OS.
Conclusions
severe obesity (BMI >40) have worse overall survival with no impact on disease free survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
920 - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)
Presenter: Lee Schwartzberg
Session: Poster Display session 1
Resources:
Abstract
5146 - Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy
Presenter: Smitha Saldanha
Session: Poster Display session 1
Resources:
Abstract
1947 - Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-receiving patients - A prospective multicenter trial
Presenter: Meinolf Karthaus
Session: Poster Display session 1
Resources:
Abstract
6163 - A study evaluating steroid induced metabolic syndrome after antiemetic dexamethasone therapy in patients received high emetic risk chemotherapy
Presenter: Hee Jun Kim
Session: Poster Display session 1
Resources:
Abstract
2154 - High incidence of nausea during initial and repeated courses if intravenous chemotherapy in patients receiving guideline consistent antiemetic prophylaxis - a prospective, observational, real world study.
Presenter: Teresa Smit
Session: Poster Display session 1
Resources:
Abstract
1637 - "Randomised controlled trial of Scalp Cooling (SC) for the prevention of Chemotherapy Induced Alopecia (CIA)”
Presenter: Jyoti Bajpai
Session: Poster Display session 1
Resources:
Abstract
5351 - Performance of the ‘4S rule’ to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism.
Presenter: David Pesántez Coronel
Session: Poster Display session 1
Resources:
Abstract
1189 - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
Presenter: Shota Omori
Session: Poster Display session 1
Resources:
Abstract
4340 - Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis.
Presenter: Diego Muñoz Guglielmetti
Session: Poster Display session 1
Resources:
Abstract
4658 - Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
Presenter: Alexander Cohen
Session: Poster Display session 1
Resources:
Abstract